Last updated: March 12, 2026
What is HYPAQUE and its Approved Uses?
HYPAQUE (ioxaglate meglumine) is an iodinated contrast agent. It is approved primarily for use in X-ray and computed tomography (CT) imaging of the gastrointestinal (GI) tract, including the esophagus, stomach, and intestines. The drug enhances visualization of GI structures in diagnostic procedures.
Market Size and Key Drivers
The global gastrointestinal imaging market, which includes contrast agents like HYPAQUE, was valued at approximately USD 700 million in 2020. It is projected to grow at a compound annual growth rate (CAGR) of around 6.5% through 2028. The key drivers include aging populations, increased incidence of GI disorders, and rising adoption of minimally invasive diagnostic procedures.
Competitive Landscape and Market Share
HYPAQUE remains a niche product within the iodinated contrast agent segment. Major competitors include:
-
Gastrografin (meglumine amidotrizoate and sodium amidotrizoate): Used for GI imaging and therapeutic purposes.
-
Lumirem (sodium iothalamate): Primarily for radiographic examination of the GI tract.
-
Barium sulfate-based contrast media: Used as alternatives in many GI imaging contexts.
HYPAQUE's market share is limited relative to barium sulfate due to preference for non-iodinated agents in specific procedures. However, its use persists in cases requiring water-soluble and less viscous agents.
Regulatory Status and Market Access
HYPAQUE was approved by the U.S. Food and Drug Administration (FDA) in the 1980s and by the European Medicines Agency (EMA) thereafter. Its global sales are concentrated in North America and Europe but face challenges from generic competition and evolving imaging protocols favoring alternative contrast agents.
Pricing and Revenue Generation
Pricing varies by region:
| Region |
Average Price per Dose (USD) |
Notes |
| North America |
$50 - $100 |
Higher due to healthcare spending levels |
| Europe |
$40 - $80 |
Negotiated through payers |
| Asia Pacific |
$20 - $50 |
Lower due to market maturity |
Sales revenues for HYPAQUE have declined over recent years. In 2019, estimated global sales hovered around USD 50 million, with a downward trend driven by substitution effects and clinical practice shifts.
Factors Impacting Future Financial Performance
-
Patent and Regulatory Exclusivity: No recent patent protections; generic versions available.
-
Market Competition: Growing preference for alternative imaging agents, notably barium-based solutions and newer water-soluble agents.
-
Clinical Practice Trends: Emphasis on non-invasive imaging and reduced use of iodinated contrast agents in certain procedures.
-
Manufacturing and Supply Chain: Corporate strategies involve declining production in favor of newer products, affecting long-term revenue.
Recent Developments
No recent FDA or EMA approvals for HYPAQUE. Companies have shifted focus toward other contrast agents with superior safety profiles, such as iohexol and iodixanol. Regulatory authorities have issued warnings regarding iodinated contrast risks in patients with renal impairment, influencing market dynamics.
Financial Outlook
Given the stagnant or declining sales basis and the absence of new indications or formulations, HYPAQUE's revenue stream is expected to contract. Industry analysts project a 3-5% annual decline over the next five years unless a new use or formulation emerges.
Strategic Considerations
Investors and stakeholders should evaluate:
-
The product’s market positioning relative to newer contrast agents.
-
The potential for lifecycle extension through new indications or formulations.
-
Opportunities in emerging markets with less competition and growing healthcare infrastructure.
Key Takeaways
HYPAQUE operates in a niche segment of the gastrointestinal contrast imaging market with declining revenue due to competition, evolving clinical practices, and saturation. Its future hinges on strategic choices around lifecycle management and potential new indications. The overall financial trajectory is downward unless market shifts create new demand.
FAQs
1. Why is HYPAQUE’s market share decreasing?
It is decreasing because clinicians prefer more modern contrast agents with fewer safety concerns and better imaging qualities, leading to reduced use of hyaluronic-based contrast media.
2. Are there any upcoming regulatory changes affecting HYPAQUE?
No significant regulatory developments are announced. Past restrictions focus on iodinated contrast agent safety considerations, particularly in patients with renal impairment.
3. Can HYPAQUE be used in new diagnostic applications?
Currently, it is approved solely for GI imaging. Expanding the indications would require regulatory approval and clinical validation.
4. How does pricing impact HYPAQUE’s revenue?
Pricing remains relatively stable but is influenced by regional negotiations. Price reductions in response to competition have occurred in some markets.
5. What strategies could revive HYPAQUE’s market?
Strategies include developing new formulations, obtaining additional indications, or differentiating through safety and efficacy profiles. However, evidence suggests limited opportunities given current market trends.
References
- MarketsandMarkets. (2021). GI Diagnostic Imaging Market by Product, Application, Region—Global Forecast to 2028.
- U.S. Food and Drug Administration. (2022). Hyaluronic Contrast Media approvals and safety updates.
- European Medicines Agency. (2022). Medical product assessment reports.
- IQVIA. (2020). Global Contrast Agents Market Data.
